期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 64, 期 11, 页码 7241-7260出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.1c00343
关键词
-
Mutations in the CFTR ion channel are linked to cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). A potential drug, icenticaftor (QBW251), has shown positive clinical results for CF and COPD patients. This study provides insights into the pathogenesis of these lung diseases and offers a novel therapeutic approach for COPD patients.
Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel are established as the primary causative factor in the devastating lung disease cystic fibrosis (CF). More recently, cigarette smoke exposure has been shown to be associated with dysfunctional airway epithelial ion transport, suggesting a role for CFTR in the pathogenesis of chronic obstructive pulmonary disease (COPD). Here, the identification and characterization of a high throughput screening hit 6 as a potentiator of mutant human F508del and wild-type CFTR channels is reported. The design, synthesis, and biological evaluation of compounds 7-33 to establish structure-activity relationships of the scaffold are described, leading to the identification of clinical development compound icenticaftor (QBW251) 33, which has subsequently progressed to deliver two positive clinical proofs of concept in patients with CF and COPD and is now being further developed as a novel therapeutic approach for COPD patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据